Galectin Therapeutics Inc GALT

Healthcare Biotechnology

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. Galectin Therapeutics Inc. has a collaborative joint venture co-owned by SBH Sciences, Inc. with Galectin Sciences, LLC for the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

NDAQ:GALT - Post by User

Galectin Therapeutics Inc

<< Previous

Bullboard Posts

Next >>

(48)
•••

Post by SPCEO1on Jun 25, 2018 10:24am

500 Views

Post# 28223477

Links to articles related to GALT

https://psinvestor.com/galectin-therapeutics-from-an-investor-perspective/

https://emerginggrowth.com/cancers-last-stand-gr-md-02-nearly-doubles-response-rate-added-keytruda/

https://www.fool.com/investing/2018/06/15/3-top-healthcare-stocks-to-buy-in-june.aspx

https://seekingalpha.com/news/3356229-galectin-advance-nash-candidate-gr-mdminus-02-phase-3?app=1#email_link

https://seekingalpha.com/article/4180041-galectin-therapeuticss-market-value-soar-coming-months

<< Previous

Bullboard Posts

Next >>

Team spotlight: Q+A: Charlene Duffett, Viridian Metals exploration manager